These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Epidemiological factors in clinical trial design. Wassilak S Dev Biol Stand; 1998; 95():75-83. PubMed ID: 9855417 [TBL] [Abstract][Full Text] [Related]
4. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials. Black S Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015 [TBL] [Abstract][Full Text] [Related]
5. Statistical considerations for noninferiority/equivalence trials in vaccine development. Wang WW; Mehrotra DV; Chan IS; Heyse JF J Biopharm Stat; 2006; 16(4):429-41. PubMed ID: 16892905 [TBL] [Abstract][Full Text] [Related]
6. Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials. Huang Y; Gilbert PB; Fu R; Janes H Biostatistics; 2017 Apr; 18(2):230-243. PubMed ID: 27649715 [TBL] [Abstract][Full Text] [Related]
7. Issues in the design and implementation of vaccine trials in less developed countries. Deen JL; Clemens JD Nat Rev Drug Discov; 2006 Nov; 5(11):932-40. PubMed ID: 17080029 [TBL] [Abstract][Full Text] [Related]
8. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs. Vaucher P Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773 [TBL] [Abstract][Full Text] [Related]
9. Evaluating vaccine safety before and after licensure. Clemens J Bull World Health Organ; 2000; 78(2):218-9. PubMed ID: 10743289 [TBL] [Abstract][Full Text] [Related]
10. Sequential generalized likelihood ratio tests for vaccine safety evaluation. Shih MC; Lai TL; Heyse JF; Chen J Stat Med; 2010 Nov; 29(26):2698-708. PubMed ID: 20799244 [TBL] [Abstract][Full Text] [Related]
11. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Peter G; des Vignes-Kendrick M; Eickhoff TC; Fine A; Galvin V; Levine MM; Maldonado YA; Marcuse EK; Monath TP; Osborn JE; Plotkin S; Poland GA; Quinlisk MP; Smith DR; Sokol M; Soland DB; Whitley-Williams PN; Williamson DE; Breiman RF Pediatrics; 1999 Oct; 104(4 Pt 1):942-50. PubMed ID: 10506239 [TBL] [Abstract][Full Text] [Related]
12. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA. WHO/UNAIDS/IAVI International Expert Group AIDS; 2007 Feb; 21(4):539-46. PubMed ID: 17301582 [TBL] [Abstract][Full Text] [Related]
13. Pneumococcal conjugate vaccine for young children. Selman S; Hayes D; Perin LA; Hayes WS Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663 [TBL] [Abstract][Full Text] [Related]
14. Associations of the correlates of protection and implication on the statistical power for demonstrating non-inferiority: application of a re-sampling method on a large phase III influenza vaccine clinical trial. Bugarini R; Casula D; Groth N; Lattanzi M; Holmes S; Podda A Vaccine; 2010 Oct; 28(46):7401-6. PubMed ID: 20850533 [TBL] [Abstract][Full Text] [Related]
15. Assessing the effect of HIV vaccination on infectiousness. Rida WN Stat Med; 1996 Nov 15-30; 15(21-22):2393-404; discussion 2405-12. PubMed ID: 8931209 [TBL] [Abstract][Full Text] [Related]